raav2/5-pbgd
Gene therapyexperimental
Clinical trial activity
1 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2012 (NCT02082860)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Porphobilinogen deaminaseSupplementation
HMBS supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- raav2/5-pbgd
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02082860 | Phase 1 | Nov 1, 2012 | Clinica Universidad de Navarra, Digna Biotech S.L., Porphyria Centre Sweden, UniQure N.V., Universidad Complutense de Madrid |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Clinica Universidad de Navarra | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Digna Biotech S.L. | For profit | 1 | 1 | 1 | 2012 |
| Porphyria Centre Sweden | Academic/Hospital | 1 | 0 | 1 | 2012 |
| UniQure N.V. | For profit | 1 | 0 | 1 | 2012 |
| Universidad Complutense de Madrid | Academic/Hospital | 1 | 0 | 1 | 2012 |
5 organizations
Page 1 / 1